Alnylam Pharmaceuticals Scheduled to Report Q3 2026 Earnings
Alnylam Pharmaceuticals (ALNY) is set to release its third-quarter 2026 financial results on Thursday, October 29th, prior to the market opening. Investors are closely watching for performance metrics that reflect the company's current growth trajectory in the RNAi therapeutics space. Market consensus estimates project quarterly revenue of $1.43 billion, representing a 15.3% increase year-over-year. However, earnings per share (EPS) are expected to be $2.25, which marks a significant 22.4% decline compared to the same period last year.
Tickers: $ALNY
Topics: earnings release EPS estimate financial estimates revenue forecast